|
1
|
A novel herpes simplex virus type 1 transcript (AL-RNA) antisense to the 5' end of the latency-associated transcript produces a protein in infected rabbits.
|
J Virol
|
2002
|
1.30
|
|
2
|
A fully synthetic therapeutic vaccine candidate targeting carcinoma-associated Tn carbohydrate antigen induces tumor-specific antibodies in nonhuman primates.
|
Cancer Res
|
2004
|
1.26
|
|
3
|
HLA-A*0201-restricted CD8+ cytotoxic T lymphocyte epitopes identified from herpes simplex virus glycoprotein D.
|
J Immunol
|
2008
|
1.24
|
|
4
|
The role of LAT in increased CD8+ T cell exhaustion in trigeminal ganglia of mice latently infected with herpes simplex virus 1.
|
J Virol
|
2011
|
1.18
|
|
5
|
Lipopeptide epitopes extended by an Nepsilon-palmitoyl-lysine moiety increase uptake and maturation of dendritic cells through a Toll-like receptor-2 pathway and trigger a Th1-dependent protective immunity.
|
Eur J Immunol
|
2004
|
1.14
|
|
6
|
The herpes simplex virus type 1 latency-associated transcript can protect neuron-derived C1300 and Neuro2A cells from granzyme B-induced apoptosis and CD8 T-cell killing.
|
J Virol
|
2010
|
1.12
|
|
7
|
Th-cytotoxic T-lymphocyte chimeric epitopes extended by Nepsilon-palmitoyl lysines induce herpes simplex virus type 1-specific effector CD8+ Tc1 responses and protect against ocular infection.
|
J Virol
|
2005
|
1.10
|
|
8
|
The herpes simplex virus 1 latency-associated transcript promotes functional exhaustion of virus-specific CD8+ T cells in latently infected trigeminal ganglia: a novel immune evasion mechanism.
|
J Virol
|
2011
|
1.09
|
|
9
|
Of mice and not humans: how reliable are animal models for evaluation of herpes CD8(+)-T cell-epitopes-based immunotherapeutic vaccine candidates?
|
Vaccine
|
2011
|
1.07
|
|
10
|
New concepts in herpes simplex virus vaccine development: notes from the battlefield.
|
Expert Rev Vaccines
|
2009
|
1.07
|
|
11
|
Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response.
|
Viral Immunol
|
2006
|
1.06
|
|
12
|
Level of herpes simplex virus type 1 latency correlates with severity of corneal scarring and exhaustion of CD8+ T cells in trigeminal ganglia of latently infected mice.
|
J Virol
|
2008
|
1.06
|
|
13
|
A novel HLA (HLA-A*0201) transgenic rabbit model for preclinical evaluation of human CD8+ T cell epitope-based vaccines against ocular herpes.
|
J Immunol
|
2010
|
1.06
|
|
14
|
Asymptomatic human CD4+ cytotoxic T-cell epitopes identified from herpes simplex virus glycoprotein B.
|
J Virol
|
2008
|
1.04
|
|
15
|
Stable cell lines expressing high levels of the herpes simplex virus type 1 LAT are refractory to caspase 3 activation and DNA laddering following cold shock induced apoptosis.
|
Virology
|
2007
|
1.04
|
|
16
|
The locus encompassing the latency-associated transcript of herpes simplex virus type 1 interferes with and delays interferon expression in productively infected neuroblastoma cells and trigeminal Ganglia of acutely infected mice.
|
J Virol
|
2005
|
1.04
|
|
17
|
Towards a self-adjuvanting multivalent B and T cell epitope containing synthetic glycolipopeptide cancer vaccine.
|
ChemMedChem
|
2008
|
1.03
|
|
18
|
Functional Foxp3+ CD4+ CD25(Bright+) "natural" regulatory T cells are abundant in rabbit conjunctiva and suppress virus-specific CD4+ and CD8+ effector T cells during ocular herpes infection.
|
J Virol
|
2007
|
1.02
|
|
19
|
Antitumor activity of a self-adjuvanting glyco-lipopeptide vaccine bearing B cell, CD4+ and CD8+ T cell epitopes.
|
Cancer Immunol Immunother
|
2008
|
1.00
|
|
20
|
Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines.
|
Invest Ophthalmol Vis Sci
|
2007
|
0.99
|
|
21
|
The role of a glycoprotein K (gK) CD8+ T-cell epitope of herpes simplex virus on virus replication and pathogenicity.
|
Invest Ophthalmol Vis Sci
|
2009
|
0.99
|
|
22
|
Local and systemic B cell and Th1 responses induced following ocular mucosal delivery of multiple epitopes of herpes simplex virus type 1 glycoprotein D together with cytosine-phosphate-guanine adjuvant.
|
Vaccine
|
2005
|
0.98
|
|
23
|
Linear and branched glyco-lipopeptide vaccines follow distinct cross-presentation pathways and generate different magnitudes of antitumor immunity.
|
PLoS One
|
2010
|
0.97
|
|
24
|
Engagement of TLR2 reverses the suppressor function of conjunctiva CD4+CD25+ regulatory T cells and promotes herpes simplex virus epitope-specific CD4+CD25- effector T cell responses.
|
Invest Ophthalmol Vis Sci
|
2011
|
0.96
|
|
25
|
Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system.
|
Ocul Surf
|
2006
|
0.95
|
|
26
|
Asymptomatic HLA-A*02:01-restricted epitopes from herpes simplex virus glycoprotein B preferentially recall polyfunctional CD8+ T cells from seropositive asymptomatic individuals and protect HLA transgenic mice against ocular herpes.
|
J Immunol
|
2013
|
0.95
|
|
27
|
Nasolacrimal duct closure modulates ocular mucosal and systemic CD4(+) T-cell responses induced following topical ocular or intranasal immunization.
|
Clin Vaccine Immunol
|
2010
|
0.94
|
|
28
|
Developing an asymptomatic mucosal herpes vaccine: the present and the future.
|
Future Microbiol
|
2010
|
0.92
|
|
29
|
Discovery of potential diagnostic and vaccine antigens in herpes simplex virus 1 and 2 by proteome-wide antibody profiling.
|
J Virol
|
2012
|
0.92
|
|
30
|
Gender-dependent HLA-DR-restricted epitopes identified from herpes simplex virus type 1 glycoprotein D.
|
Clin Vaccine Immunol
|
2008
|
0.92
|
|
31
|
Immunodominant "asymptomatic" herpes simplex virus 1 and 2 protein antigens identified by probing whole-ORFome microarrays with serum antibodies from seropositive asymptomatic versus symptomatic individuals.
|
J Virol
|
2012
|
0.90
|
|
32
|
Introducing point mutations into the ATGs of the putative open reading frames of the HSV-1 gene encoding the latency associated transcript (LAT) reduces its anti-apoptosis activity.
|
Microb Pathog
|
2007
|
0.89
|
|
33
|
Future viral vectors for the delivery of asymptomatic herpes epitope-based immunotherapeutic vaccines.
|
Future Virol
|
2010
|
0.86
|
|
34
|
A cancer therapeutic vaccine based on clustered Tn-antigen mimetics induces strong antibody-mediated protective immunity.
|
Angew Chem Int Ed Engl
|
2014
|
0.85
|
|
35
|
CD11c controls herpes simplex virus 1 responses to limit virus replication during primary infection.
|
J Virol
|
2011
|
0.84
|
|
36
|
Therapeutic immunization with a mixture of herpes simplex virus 1 glycoprotein D-derived “asymptomatic” human CD8+ T-cell epitopes decreases spontaneous ocular shedding in latently infected HLA transgenic rabbits: association with low frequency of local PD-1+ TIM-3+ CD8+ exhausted T cells.
|
J Virol
|
2015
|
0.84
|
|
37
|
A herpes simplex virus type 1 mutant disrupted for microRNA H2 with increased neurovirulence and rate of reactivation.
|
J Neurovirol
|
2015
|
0.83
|
|
38
|
Interferon-γ, a valuable surrogate marker of Plasmodium falciparum pre-erythrocytic stages protective immunity.
|
Malar J
|
2011
|
0.83
|
|
39
|
Recent advances in multivalent self adjuvanting glycolipopeptide vaccine strategies against breast cancer.
|
Arch Immunol Ther Exp (Warsz)
|
2009
|
0.82
|
|
40
|
Immunity to ocular and genital herpes simplex viruses infections.
|
Clin Dev Immunol
|
2012
|
0.79
|
|
41
|
HIV-1 infection impairs HSV-specific CD4(+) and CD8(+) T-cell response by reducing Th1 cytokines and CCR5 ligand secretion.
|
J Acquir Immune Defic Syndr
|
2011
|
0.79
|
|
42
|
Confocal Microscopic Analysis of a Rabbit Eye Model of High-Incidence Recurrent Herpes Stromal Keratitis.
|
Cornea
|
2016
|
0.75
|
|
43
|
Cytokine profiling in patients with VCP-associated disease.
|
Clin Transl Sci
|
2013
|
0.75
|